US4557866A - Process for the synthesis of pyrido-imidazo rifamycins - Google Patents

Process for the synthesis of pyrido-imidazo rifamycins Download PDF

Info

Publication number
US4557866A
US4557866A US06/727,521 US72752185A US4557866A US 4557866 A US4557866 A US 4557866A US 72752185 A US72752185 A US 72752185A US 4557866 A US4557866 A US 4557866A
Authority
US
United States
Prior art keywords
alkyl
rifamycin
formula
sub
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/727,521
Inventor
Vincenzo Cannata
Gian F. Tamagnone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Farmaceutici SpA
Original Assignee
Alfa Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Farmaceutici SpA filed Critical Alfa Farmaceutici SpA
Assigned to ALFA FARMACEUTICI S.P.A. reassignment ALFA FARMACEUTICI S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: CANNATA, VINCENZO, MARCHI, EGIDIO, PIANI SILVANO, TAMAGNONE, GIAN F.
Application granted granted Critical
Publication of US4557866A publication Critical patent/US4557866A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • R is hydrogen or acetyl and R 1 and R 2 independently represent hydrogen, (C 1-4 )-alkyl, benzyloxy, mono- or di-(C 1-3 )-alkylamino-(C 1-4 )-alkyl, (C 1-3 )-alkoxy-(C 1-4 )-alkyl, hydroxymethyl, hydroxy-(C 2-4 )-alkyl, nitro, or R 1 and R 2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups are known in the patent literature; see, for instance, U.S. Pat. No. 4,341,785 published on July 27, 1982.
  • R is hydrogen or acetyl and at least one of R 1 or R 2 represents halogen, cyano, mercapto, (C 1-4 )-alkylthio, phenylthio, carbamoyl, mono- or di-(C 1-4 )-alkylcarbamoyl are described in the copending Italian patent application No. 3626 A/82, now available to the public.
  • the present invention refers to a new method for preparing pyrido-imidazo-rifamycins of general formula ##STR6## wherein R is hydrogen or acetyl, R 1 and R 2 independently represent hydrogen, (C 1-4 )-alkyl, benzyloxy, mono- or di-(C 1-3 )-alkylamino-(C 1-4 )-alkyl, (C 1-3 )-alkoxy-(C 1-4 )-alkyl, hydroxymethyl, hydroxy-(C 2-4 )-alkyl, cyano, halogen, nitro, mercapto, (C 1-4 )-alkylthio, phenylthio, carbamoyl, mono- and di-(C 1-4 )-alkyl-carbamoyl, or R 1 and R 2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or eth
  • (C 1-4 )-alkyl indicates straight or branched alkyl groups as, for instance, methyl, ethyl, propyl, isopropyl, butyl, sec.-butyl, isobutyl and tert.-butyl, while the term (C 1-3 )-alkoxy mainly designates the groups methoxy, ethoxy, propoxy or isopropoxy.
  • the compounds of formula I are endowed with outstanding antibacterial properties both in vitro and in vivo. Because of their poor absorption by animal organs and tissues when administered by oral route, they have proved to be particularly useful in combatting the microbial infections of the gastro-intestinal tract.
  • rifamycin O which is a commercial product, is used as the starting rifamycin substrate [easily obtainable by chemical transformation of rifamycin B, as described in French Patent FM 739, or directly obtainable by fermentation of Nocardia strains (unexamined Japanese publication No. 15518/66) or by fermentation of Streptomyces strains (Belgian patent No. 751182)].
  • the rifamycin O is reacted under mild conditions with a selected 2-aminopyridine of formula III, in a suitable solvent or solvent system from which, by means of techniques known to a man skilled in the art, the desired end products are recovered, wherein R 1 and R 2 have the above mentioned meanings and R is acetyl, with yields varying from about 60% to about 90% calculated on the starting rifamycin O.
  • the compounds of formula I so obtained can subsequently be subjected to an alkaline hydrolysis to give the corresponding compounds of formula I wherein R is hydrogen.
  • a molar amount of rifamycin O of formula II is reacted with from about 1 to about 9 molar equivalents of a 2-aminopyridine of formula III and, preferably, from about 2 to about 6 molar equivalents of said aminopyridine.
  • the reaction is carried out in the presence of a solvent or of a solvent system, which is generally selected among those commonly used in rifamycins chemistry.
  • a solvent or of a solvent system which is generally selected among those commonly used in rifamycins chemistry.
  • aromatic hydrocarbons like benzene and toluene
  • lower halogenated hydrocarbons like methylene chloride, chloroform, 1,2-dichloroethane and analogs
  • lower alkanols like methanol, ethanol, propanol, isopropanol or n-butanol
  • Lower alkyl esters of lower aliphatic acids, glycols, acetonitrile, dioxane and tetrahydrofuran can also conveniently be employed.
  • solvents can be used alone, or in admixture among them, or also in admixture with water, in different volumetric ratios.
  • the solvents which have given the best results are benzene, toluene, the lower halogenated hydrocarbons, the lower alkanols alone or in admixture with water, acetonitrile, glycols, dioxane and tetrahydrofuran.
  • the reaction takes place at ambient pressure and within wide limits of temperature, for instance between the room temperature and the boiling temperature of the reaction mixture. Usually, an interval comprised between the room temperature and about 60° C. gives absolutely satisfactory results.
  • the reaction is completed in a period of time which essentially depends on the nature of the aminopyridine substrate of formula III and on the conditions in which the reaction is carried out. Generally, from about 10 to about 100 hours are required to obtain the end products of formula I with the desired yields.
  • the reaction course can be favored if the reaction itself is carried out in presence of iodine or of an appropriate system iodide/oxidizing agent, wherein the iodide can be, for instance, the iodide of an alkali or an alkaline-earth metal and the hydroiodide of the same starting 2-amino-piridine and the oxidizing agent can be an agent capable of oxidizing, in the employed reaction conditions, the iodide ion, in order to release iodine in the reaction ambient.
  • the iodide can be, for instance, the iodide of an alkali or an alkaline-earth metal and the hydroiodide of the same starting 2-amino-piridine
  • the oxidizing agent can be an agent capable of oxidizing, in the employed reaction conditions, the iodide ion, in order to release iodine in the reaction ambient.
  • the iodine, or the system iodide/oxidizing agent can be present in the reaction ambient respectively in amounts from about 0.1 to about 1 molar equivalent, or in an amount which releases from about 0.1 to about 1 molar equivalent of iodine, for each mole of starting rifamycin O.
  • reaction solution must subsequently be treated with a suitable reducing agent, like, for instance, ascorbic acid, isoascorbic acid or dihydroxyacetone.
  • a suitable reducing agent like, for instance, ascorbic acid, isoascorbic acid or dihydroxyacetone.
  • the so obtained compounds of formula I in which R is the acetyl group are recovered from the reaction medium according to conventional techniques.
  • the excess of unreacted aminopyridine of formula III is eliminated from the organic phase by means of an aqueous solution of a mineral acid.
  • the organic phase is then separated and optionally dried on a suitable agent like, for instance, sodium sulfate, and the end product is obtained by evaporating the solvent.
  • the desired compounds are obtained by crystallization from the reaction ambient at a temperature of about 0° to 10° C. when solvent systems containing water are used.
  • the compounds of formula I can be purified, if necessary, by crystallization from suitable solvents or solvent systems.
  • the I.R. spectra have been performed in KBr with a Perkin-Elmer 281-B spectrophotometer.
  • the 1 H-NMR and 13 C-NMR spectra have been performed in deuterochloroform with a Varian XL 100 spectrophotometer by using tetramethylsilane as internal standard.
  • the U.V. spectra have been performed in absolute methanol with a Perkin-Elmer 552 spectrophotometer.
  • the so obtained compound has the same chemico-physical characteristics as that obtained in Example 1.
  • the compound was prepared according to the procedure described in example 2, starting from 15.1 g (0.02 moles) of rifamycin O and 6.48 g (0.06 moles) of 2-amino-5-methyl-pyridine. Yield 12.6 g (80% of theoretical). M.p. 193°-198° C. (decomposition).
  • Example 7 The procedure of example 7 is repeated, keeping the reaction solution at room temperature for 20 hours and in presence of 11 g (0.043 moles) of iodine. After treatment with 130 ml of aqueous 20% solution of ascorbic acid, 160.4 g (77% of theoretical) of title compound were obtained, identical with that obtained in Example 1.
  • Example 10 By employing the same molar ratio rifamycin O/2-amino-4-methyl-pyridine as in Example 10, using 450 ml of a 10:13 (v/v) mixture of ethanol/water and working under the same reaction conditions of Example 9, 91 g of pure title product were obtained with a yield of 86.7% of theoretical.

Abstract

A new process for the synthesis of pyrido-imidazo-rifamycins of formula ##STR1## wherein R is hydrogen or acetyl, R1 and R2 independently represent hydrogen, (C1-4)-alkyl, benzyloxy, mono- or di-(C1-3)-alkylamino-(C1-4)-alkyl, (C1-3)-alkoxy-(C1-4)-alkyl, hydroxymethyl, hydroxy-(C2-4)-alkyl, cyano, halogen, nitro, mercapto, (C1-4)-alkylthio, phenylthio, carbamoyl, mono- or di-(C1-4)-alkyl-carbamoyl, or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups.
The process comprises reacting the rifamycin O of formula ##STR2## with a 2-aminopyridine of formula ##STR3## wherein R1 and R2 have the same meanings as before.

Description

BACKGROUND OF THE INVENTION
Some of the compounds of formula I, more exactly those wherein R is hydrogen or acetyl and R1 and R2 independently represent hydrogen, (C1-4)-alkyl, benzyloxy, mono- or di-(C1-3)-alkylamino-(C1-4)-alkyl, (C1-3)-alkoxy-(C1-4)-alkyl, hydroxymethyl, hydroxy-(C2-4)-alkyl, nitro, or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups are known in the patent literature; see, for instance, U.S. Pat. No. 4,341,785 published on July 27, 1982.
Other compounds of formula I, more exactly those wherein R is hydrogen or acetyl and at least one of R1 or R2 represents halogen, cyano, mercapto, (C1-4)-alkylthio, phenylthio, carbamoyl, mono- or di-(C1-4)-alkylcarbamoyl are described in the copending Italian patent application No. 3626 A/82, now available to the public.
In these two references a process for obtaining the compounds of formula I was also described.
Briefly, the known process was carried out by reacting a molar amount of a 3-halogen rifamycin S of formula ##STR4## wherein R represented hydrogen or acetyl and halo preferably represented bromine or iodine, with from about 2 to about 8 molar equivalents of an appropriate 2-amino-pyridine of formula III.
A compound of formula ##STR5## was obtained, which was preferably isolated and characterized, and was subsequently treated with ascorbic acid in order to give the end compounds of formula I.
Notwithstanding the yields of the two cited steps, calculated on the starting compound IV, are sometimes quite good (they are comprised between about 45% and about 75%), the process described in the U.S. patent is strongly limited by the fact that the starting compound IV is not a commercial product, but has to be prepared every time starting from rifamycin S with suitable, often troublesome, processes of halogenation. This fact causes the process described either in U.S. Pat. No. 4,341,785 and in the copending Italian application 3626 A/82 to run with yields far lower than those above mentioned, thus giving the desired compounds with unsatisfactory yields from an industrial point of view.
SUMMARY OF THE INVENTION
The present invention refers to a new method for preparing pyrido-imidazo-rifamycins of general formula ##STR6## wherein R is hydrogen or acetyl, R1 and R2 independently represent hydrogen, (C1-4)-alkyl, benzyloxy, mono- or di-(C1-3)-alkylamino-(C1-4)-alkyl, (C1-3)-alkoxy-(C1-4)-alkyl, hydroxymethyl, hydroxy-(C2-4)-alkyl, cyano, halogen, nitro, mercapto, (C1-4)-alkylthio, phenylthio, carbamoyl, mono- and di-(C1-4)-alkyl-carbamoyl, or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups.
In the context of the invention, the term (C1-4)-alkyl indicates straight or branched alkyl groups as, for instance, methyl, ethyl, propyl, isopropyl, butyl, sec.-butyl, isobutyl and tert.-butyl, while the term (C1-3)-alkoxy mainly designates the groups methoxy, ethoxy, propoxy or isopropoxy.
The compounds of formula I are endowed with outstanding antibacterial properties both in vitro and in vivo. Because of their poor absorption by animal organs and tissues when administered by oral route, they have proved to be particularly useful in combatting the microbial infections of the gastro-intestinal tract.
The process described in the present invention represents a remarkable improvement in comparison with the prior art method. In fact rifamycin O, which is a commercial product, is used as the starting rifamycin substrate [easily obtainable by chemical transformation of rifamycin B, as described in French Patent FM 739, or directly obtainable by fermentation of Nocardia strains (unexamined Japanese publication No. 15518/66) or by fermentation of Streptomyces strains (Belgian patent No. 751182)].
The rifamycin O is reacted under mild conditions with a selected 2-aminopyridine of formula III, in a suitable solvent or solvent system from which, by means of techniques known to a man skilled in the art, the desired end products are recovered, wherein R1 and R2 have the above mentioned meanings and R is acetyl, with yields varying from about 60% to about 90% calculated on the starting rifamycin O. The compounds of formula I so obtained can subsequently be subjected to an alkaline hydrolysis to give the corresponding compounds of formula I wherein R is hydrogen.
The reaction between the compounds of formula II and III therefore runs in only one step and is illustrated by the following scheme which does not report the optional hydrolytic step R═COCH3 →R═H. ##STR7##
In practice, a molar amount of rifamycin O of formula II, is reacted with from about 1 to about 9 molar equivalents of a 2-aminopyridine of formula III and, preferably, from about 2 to about 6 molar equivalents of said aminopyridine.
The reaction is carried out in the presence of a solvent or of a solvent system, which is generally selected among those commonly used in rifamycins chemistry. For instance, aromatic hydrocarbons, like benzene and toluene, lower halogenated hydrocarbons, like methylene chloride, chloroform, 1,2-dichloroethane and analogs, lower alkanols, like methanol, ethanol, propanol, isopropanol or n-butanol, are advantageously used. Lower alkyl esters of lower aliphatic acids, glycols, acetonitrile, dioxane and tetrahydrofuran can also conveniently be employed. These solvents can be used alone, or in admixture among them, or also in admixture with water, in different volumetric ratios. The solvents which have given the best results are benzene, toluene, the lower halogenated hydrocarbons, the lower alkanols alone or in admixture with water, acetonitrile, glycols, dioxane and tetrahydrofuran.
The reaction takes place at ambient pressure and within wide limits of temperature, for instance between the room temperature and the boiling temperature of the reaction mixture. Usually, an interval comprised between the room temperature and about 60° C. gives absolutely satisfactory results.
The reaction is completed in a period of time which essentially depends on the nature of the aminopyridine substrate of formula III and on the conditions in which the reaction is carried out. Generally, from about 10 to about 100 hours are required to obtain the end products of formula I with the desired yields. It has been found, however, that, sometimes, the reaction course can be favored if the reaction itself is carried out in presence of iodine or of an appropriate system iodide/oxidizing agent, wherein the iodide can be, for instance, the iodide of an alkali or an alkaline-earth metal and the hydroiodide of the same starting 2-amino-piridine and the oxidizing agent can be an agent capable of oxidizing, in the employed reaction conditions, the iodide ion, in order to release iodine in the reaction ambient. The iodine, or the system iodide/oxidizing agent, can be present in the reaction ambient respectively in amounts from about 0.1 to about 1 molar equivalent, or in an amount which releases from about 0.1 to about 1 molar equivalent of iodine, for each mole of starting rifamycin O.
In such a case, however, the reaction solution must subsequently be treated with a suitable reducing agent, like, for instance, ascorbic acid, isoascorbic acid or dihydroxyacetone.
The above described operations are carried out without separating any intermediate, so preserving the "one step reaction" character typical of the process of the present invention.
The so obtained compounds of formula I in which R is the acetyl group are recovered from the reaction medium according to conventional techniques. Thus, for instance, the excess of unreacted aminopyridine of formula III is eliminated from the organic phase by means of an aqueous solution of a mineral acid. The organic phase is then separated and optionally dried on a suitable agent like, for instance, sodium sulfate, and the end product is obtained by evaporating the solvent. Alternatively, the desired compounds are obtained by crystallization from the reaction ambient at a temperature of about 0° to 10° C. when solvent systems containing water are used.
The compounds of formula I can be purified, if necessary, by crystallization from suitable solvents or solvent systems.
Subsequently, the products of formula I wherein R is acetyl can be transformed into the corresponding compounds wherein R is hydrogen by means of a mild alkaline hydrolysis. Alternatively, the same starting rifamycin O can be transformed into the corresponding desacetyl derivative on which the process of the invention can be carried out according to scheme I.
The invention is illustrated by means of the following examples which, however, have not to be interpreted as a limitation of the scope of the invention.
The I.R. spectra have been performed in KBr with a Perkin-Elmer 281-B spectrophotometer.
The 1 H-NMR and 13 C-NMR spectra have been performed in deuterochloroform with a Varian XL 100 spectrophotometer by using tetramethylsilane as internal standard. The U.V. spectra have been performed in absolute methanol with a Perkin-Elmer 552 spectrophotometer.
EXAMPLE 1 4-Deoxy-4'-methyl-pyrido[1',2':1,2]imidazo-[5,4-c]rifamycin SV
7.54 Grams (0.01 moles) of rifamycin O and 3.24 g (0.03 moles) of 2-amino-4-methyl-pyridine were dissolved in 40 ml of methylene chloride and the so obtained solution was kept at room temperature for 48 hours. After washing the reaction mixture first with 60 ml of an aqueous 1N solution of hydrochloric acid and then with water, and drying the organic phase over sodium sulfate, the methylene chloride was eliminated by evaporation under vacuum.
A residue was obtained which was crystallized by ethanol and water 7:3 (v/v). Yield 6.13 g (78% of theoretical). M.p. 200°-205° C. (decomposition).
______________________________________                                    
U.V. Spectrum:  λ max (mμ)                                      
                          E .sub.1cm.sup.1%                               
______________________________________                                    
              232     489                                                 
              260     339                                                 
              292     295                                                 
              320     216                                                 
              370     119                                                 
              450     159                                                 
______________________________________
I.R. Spectrum: characteristic absorption bands were observed at the following frequencies (in cm-1): 3440 (b), 2960 (s), 2920 (s), 2860 (w), 2820 (vw), 1705 (s), 1640 (s), 1580 (s), 1500 (s). b=broad, s=strong, w=weak, vw=very weak.
1 H-NMR Spectrum: characteristic resonance peaks were observed at the following δ (expressed as p.p.m.): -0.56 (d,3H); 0.14 (d,3H); 0.74 (d,3H); 0.94 (d,3H); 1.94 (s,3H); 1.98 (s,3H); 2.02 (s,3H); 2.26 (s,3H); 2.63 (s,3H); 3.00 (s,3H); 3.2-3.9 (m,3H); 4.15-5.20 (m,2H); 5.9-6.9 (m,4H); 7.06 (dd,1H); 7.38 (s,1H); 8.39 (s,1H); 8.43 (d,1H); 11.0 (s,1H); 13.12 (s,1H). s=singlet; d=doublet; m=multiplet; dd=doublet of doublet.
13 C-NMR Spectrum: characteristic resonance peaks were observed at the following δ (expressed as p.p.m.): 6.98; 8.06; 8.21; 10.76; 17.56; 20.43; 20.78; 21.44; 22.35; 32.91; 36.93; 37.78; 38.59; 56.99; 72.65; 73.91; 76.75; 77.86; 97.83; 103.86; 104.09; 108.97; 109.99; 112.03; 114.96; 115.52; 117.61; 119.26; 122.99; 125.35; 128.44; 128.96; 136.21; 138.87; 141.75; 142.10; 147.74; 155.10; 170.63; 171.89; 182.19; 188.84.
EXAMPLE 2 4-Deoxy-isoquinolino[2',1':1,2]imidazo[5,4-c]rifamycin SV
By substantially operating as described in the preceding example, starting from 7.54 g (0.01 moles) of rifamycin O and 4.32 g (0.03 moles) of 1-amino-isoquinoline, 6.07 g of the title compound were obtained (74% of theoretical). M.p. 181°-186° C. (decomposition).
______________________________________                                    
U.V. Spectrum:  λ max (mμ)                                      
                          E .sub.1cm.sup.1%                               
______________________________________                                    
              253     532                                                 
              288     363                                                 
              300     346                                                 
              320     290                                                 
              382     120                                                 
              430     129                                                 
______________________________________
I.R. Spectrum: characteristic absorption bands were observed at the following frequencies (in cm-1): 3440 (b), 3140 (b), 2910 (s), 2850 (w), 1700 (s), 1630 (b), 1610(b), 1580 (w), 1555 (vw), 1535 (vw) b=broad; s=strong; w=weak; vw=very weak.
1 H-NMR Spectrum: Characteristic resonance peaks were observed at the following δ (expressed as p.p.m.): -0.65 (d,3H); 0.04 (d,3H); 0.7 (d,3H); 0.88 (d,3H); 1.55 (s,3H); 1.92 (s,3H); 2.02 (s,3H); 2.27 (s,3H); 2.77 (d,1H); 2.94 (s,3H); 3.00-3.90 (m,4H); 4.78 (d,1H); 4.93 (q,1H); 5.75-7.00 (m,4H); 7.34 (d,1H); 7.6-8.0 (m,6H); 16.6 (m,1H). s=singlet, d=doublet; m=multiplet; q=quartet
EXAMPLE 3 3'-Bromo-4-deoxy-pyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV
By operating as described in example 1, starting from 15.1 g (0.02 moles) of rifamycin O and 6.92 g (0.04 moles) of 2-amino-5-bromo-pyridine, 13.6 g (yield 80% of theoretical) were obtained.
______________________________________                                    
U.V. Spectrum:  λ max (mμ)                                      
                          E .sub.1cm.sup.1%                               
______________________________________                                    
              225     481                                                 
              238     502                                                 
              298     345                                                 
              330     185                                                 
              378     107                                                 
              450     133                                                 
______________________________________
I.R. Spectrum: characteristic absorption bands were observed at the following frequencies (in cm-1): 3440 (b); 3220 (w); 2960 (s); 2925 (m); 2870 (m); 1725 (w); 1715 (s); 1655 (w); 1635 (s); 1600 (vs). b=broad; m=medium; w=weak; s=strong; vs=very strong.
1 H-NMR Spectrum: characteristic resonance peaks were observed at the following δ (expressed as p.p.m.): -0.56 (d,3H); 0.13 (d,3H); 0.80 (d,3H); 0.85 (d,3H); 1.91 (s,3H); 1.94 (s,3H); 2.02 (s,3H); 2.26 (s,3H); 2.98 (s,3H); 2.60-3.00 (m,1H); 3.25 (d,1H); 3.56 (s,1H); 3.38-3.80 (m,2H); 4.84 (d,1H); 5.00 (q,1H); 6.02 (d,1H); 6.00-7.00 (m,3H); 7.60 (d,1H); 7.87 (q,1H); 8.39 (s,1H); 8.56 (d,1H); 16.80 (s,1H) s=singlet; d=doublet; q=quartet; m=multiplet.
13 C-NMR Spectrum: characteristic resonance peaks were observed at the following δ (expressed as p.p.m.): 7.13; 8.17; 10.86; 17.47; 20.41; 20.73; 21.28; 33.07; 37.12; 38.08; 38.77; 57.01; 72.94; 73.92; 76.80; 77.88; 98.48; 103.82; 105.11; 108.96; 109.28; 112.59; 112.81; 115.57; 116.33; 120.94; 123.38; 125.22; 129.06; 136.03; 136.80; 137.46; 141.96; 170.92; 171.59; 171.81; 182.62; 187.68.
EXAMPLE 4 4-Deoxy-4'-methyl-pyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV
A solution of 3.47 g (0.0046 moles) of rifamycin O, 1.49 g (0.0138 moles) of 2-amino-4-methyl-pyridine and 0.28 g (0.0011 moles) of iodine in 20 ml of methylene chloride was kept at room temperature for 24 hours. After adding 2 ml of an aqueous 20% solution of ascorbic acid and stirring for 30 minutes, the reaction mixture was first washed with 40 ml of an aqueous 1N solution of hydrochloric acid and then with water to neutrality.
The organic phase was recovered, dried over sodium sulfate and evaporated under vacuum to obtain a residue which was crystallized by ethanol/water 7/3 (v/v). Yield 3.15 g (87% of theoretical).
The so obtained compound has the same chemico-physical characteristics as that obtained in Example 1.
EXAMPLE 5 4-Deoxy-3'-methyl-pyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV
The compound was prepared according to the procedure described in example 2, starting from 15.1 g (0.02 moles) of rifamycin O and 6.48 g (0.06 moles) of 2-amino-5-methyl-pyridine. Yield 12.6 g (80% of theoretical). M.p. 193°-198° C. (decomposition).
______________________________________                                    
U.V. Spectrum:  λ max (mμ)                                      
                          E .sub.1cm.sup.1%                               
______________________________________                                    
              218     493                                                 
              244     433                                                 
              258     338                                                 
              274     301                                                 
              294     315                                                 
              304     207                                                 
              360     104                                                 
              373     123                                                 
              448     166                                                 
______________________________________
I.R. Spectrum: characteristic absorption bands were observed at the following frequencies (in cm-1): 3340 (b), 3300 (b), 2960 (s), 2925 (s), 2870 (vw), 2850 (s), 1730 (s), 1710 (vw), 1650 (vw), 1640 (s), 1600 (vw), 1585 (s), 1565 (w), 1525 (vw), 1505 (s) b=broad; s=strong; w=weak; vw=very weak.
1 H-NMR Spectrum: characteristic resonance peaks were observed at the following δ (expressed as p.p.m.): -0.7 (d,3H); 0.05 (d,3H); 0.68 (d,3H); 0.87 (d,3H); 1.73 (s,3H); 1.92 (s,3H); 1.97 (s,3H); 2.23 (s,3H); 2.63 (s,3H); 2.92 (s,3H); 3.25-4.00 (m,5H); 4.6-5.10 (m,2H); 5.9-6.8 (m,4H); 7.13 (q,1H); 7.6 (q,1H); 8.48 (q,1H); 14.14 (s,1H); 16.65 (s,1H) s=singlet; d=doublet; m=multiplet; q=quartet
EXAMPLE 6 4-Deoxy-4'-methyl-pyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV
3.47 Grams (0.0046 moles) of rifamycin O, 1.49 g (0.0138 moles) of 2-amino-4-methyl-pyridine and 0.28 g (0.0011 moles) of iodine were dissolved in 15 ml of a 7/3 (v/v) mixture of ethanol/water. The resulting solution was stirred for 18 hours at room temperature, then 0.28 g of iodine were added and stirring was continued for further 2 hours. The reaction mixture was added with 0.53 g (0.003 moles) of ascorbic acid and left standing for 2 days at a temperature of about 5° C. The end product crystallized which, after filtration and drying, weighted 2.35 g (65% of theoretical). The compound has the same chemico-physical characteristics as that obtained in Example 1.
EXAMPLE 7 4-Deoxy-4'-methyl-pyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV
200 Grams (0.265 moles) of rifamycin O and 65.5 g (0.607 moles) of 2-amino-4-methyl-pyridine were dissolved in 1000 ml of methylene chloride and were kept at room temperature for 40 hours. The reaction mixture was washed with 900 ml of an aqueous 1N solution of hydrochloric acid and then with water to neutrality. The washing liquors were cast off, the organic layer was dried over sodium sulfate and, after evaporating the solvent under vacuum, a residue was obtained which was crystallized from a 7/3 (v/v) mixture of ethanol/water. Yield 177 g (85% of theoretical). The compound has the same chemico-physical characteristics as that obtained in Example 1.
EXAMPLE 8 4-Deoxy-4'-methyl-pyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV
The procedure of example 7 is repeated, keeping the reaction solution at room temperature for 20 hours and in presence of 11 g (0.043 moles) of iodine. After treatment with 130 ml of aqueous 20% solution of ascorbic acid, 160.4 g (77% of theoretical) of title compound were obtained, identical with that obtained in Example 1.
EXAMPLE 9 4-Deoxy-4'-methyl-pyrido-[1',2':1,2]imidazo[5,4-c]rifamycin SV
100 Grams (0.132 moles) of rifamycin O and 57.1 g (0.528 moles) of 2-amino-4-methyl-pyridine were stirred in 400 ml of a 1:1 (v/v) mixture of ethanol/water at room temperature for 20 hours. The obtained solid was washed with a 1:1 (v/v) mixture of ethanol/water and then dried under vacuum, thus obtaining 86 g of pure product having the same chemico-physical characteristics as that obtained in Example 1, with a yield of 82% of theoretical.
EXAMPLE 10 4-Deoxy-4'-methyl-pyrido-[1',2':1,2]imidazo[5,4-c]rifamycin SV
By substantially operating according to Example 9, employing a smaller quantity of 2-amino-4-methyl-pyridine, ie. 42.8 g (0.396 moles), 83.5 g of pure title product were obtained with a yield of 79.5% of theoretical.
EXAMPLE 11 4-Deoxy-4'-methyl-pyrido-[1',2':1,2]imidazo[5,4-c]rifamycin SV
By employing the same molar ratio rifamycin O/2-amino-4-methyl-pyridine as in Example 10, using 450 ml of a 10:13 (v/v) mixture of ethanol/water and working under the same reaction conditions of Example 9, 91 g of pure title product were obtained with a yield of 86.7% of theoretical.
EXAMPLE 12 4-Deoxy-4'-methyl-pyrido-[1',2':1,2]imidazo[5,4-c]rifamycin SV
6.0 Grams (0.008 moles) of rifamycin O and 3.24 g of 2-amino-4-methyl-pyridine were stirred in 12 ml of a 9:1 (v/v) mixture of propylene glycol/ethanol for 18 hours at room temperature and the obtained mixture was left standing for 72 hours. After diluting with 16 ml of a 1:1 (v/v) mixture of 2N aqueous hydrochloric acid/ethanol the reaction mixture was filtered, the solid was collected, washed with a 1:1 (v/v) mixture of ethanol/water and dried to give 4.2 g of pure title product with a yield of 67% of theoretical.
EXAMPLE 13 4-Deoxy-4'-methyl-pyrido-[1',2':1,2]imidazo-[5,4-c]rifamycin SV
10 Grams (0.013 moles) of rifamycin O and 4.3 g (0.039 moles) of 2-amino-4-methyl-pyridine were stirred in 30 ml of a 3:2 (v:v) mixture of isopropanol/water for 16 hours at room temperature. The reaction mixture was subsequently filtered, the solid was washed with the same mixture of solvents used in the reaction and dried under vacuum to give 8.7 g of pure title product with a yield of 83% of theoretical.
EXAMPLE 14 4-Deoxy-4'-methyl-pyrido-[1',2':1,2]imidazo[5,4-c]rifamycin SV
By substantially operating according to Example 13, and employing tert.-butanol instead of isopropanol, 7.2 g of pure title product were obtained with a yield of 69% of theoretical.
The following compounds of formula I were prepared according to the procedures described in the foregoing Examples.
______________________________________                                    
R        R.sub.1      R.sub.2                                             
______________________________________                                    
COCH.sub.3                                                                
         H                                                                
4'-CH.sub.2 OH                                                            
COCH.sub.3                                                                
         H                                                                
4'-CH.sub.2 --CH.sub.2 --N(CH.sub.3).sub.2                                
COCH.sub.3                                                                
         H                                                                
4'-CH.sub.2 --N(CH.sub.3).sub.2                                           
COCH.sub.3                                                                
         H                                                                
4'-OCH.sub.2 C.sub.6 H.sub.5                                              
COCH.sub.3                                                                
         H                                                                
4'-NO.sub.2                                                               
COCH.sub.3                                                                
3-CH.sub.3                                                                
4'-CH.sub.2 --CH.sub.2 --CG.sub.2 --N(CH.sub.3)                           
COCH.sub.3                                                                
5'-CH.sub.3                                                               
3'-CH.sub.2 --CH.sub.2 --N(CH.sub.3).sub.2                                
COCH.sub.3                                                                
         H                                                                
3'-SH                                                                     
COCH.sub.3                                                                
3'-Br                                                                     
5'-Br                                                                     
COCH.sub.3                                                                
         H                                                                
3'-CH.sub.3                                                               
COCH.sub.3                                                                
         H                                                                
4'-CO--NH.sub.2                                                           
COCH.sub.3                                                                
         H                                                                
4'-CO--N(CH.sub.3).sub.2                                                  
COCH.sub.3                                                                
3'-Br                                                                     
4'-CH.sub.2 --N(CH.sub.3).sub.2                                           
COCH.sub.3                                                                
         H                                                                
4'-S--C.sub.6 H.sub.5                                                     
______________________________________

Claims (4)

We claim:
1. A new process for the preparation of pyrido-imidazo rifamycins of formula ##STR8## wherein R is hydrogen or acetyl, R1 and R2 independently represent hydrogen, (C1-4)-alkyl, benzyloxy, mono- or di-(C1-3)-alkylamino-(C1-4)-alkyl, (C1-3)-alkoxy-(C1-4)-alkyl, hydroxymethyl, hydroxy-(C2-4)-alkyl, cyano, halogen, nitro, mercapto, (C1-4)-alkylthio, phenylthio, carbamoyl, mono- or di-(C1-4)-alkyl-carbamoyl, or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus, form a benzene ring optionally substituted by 1 or 2 methyl or ethyl groups, which comprises reacting a molar equivalent of rifamycin O of formula ##STR9## with from about 1 to about 9 molar equivalents of a 2-aminopyridine of formula ##STR10## in the presence of a solvent or a solvent system, at a temperature comprised between about the room temperature and the boiling temperature of the reaction mixture, for a period of time comprised between about 10 and about 100 hours, optionally in presence of iodine or of a system iodide/oxidizing agent, and recovering the end products by means of known techniques.
2. A process as defined in claim 1, wherein for each molar equivalent of rifamycin O, from about 2 to about 6 molar equivalents of 2-aminopyridine of formula III are used.
3. A process as defined in claim 1, wherein the solvent or solvent system is selected among lower halogenated hydrocarbons, lower alkanols, lower alkyl esters of lower aliphatic acids, acetonitrile, glycols, dioxane, tetrahydrofuran alone or in admixture among them or in admixture with water in different volumetric ratios.
4. A process as defined in claim 1, wherein, for each molar equivalent of rifamycin O, from about 0.1 to about 1 molar equivalents of iodine or of a system iodide/oxidizing agent is used.
US06/727,521 1984-05-15 1985-04-26 Process for the synthesis of pyrido-imidazo rifamycins Expired - Lifetime US4557866A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT03463/84A IT1199374B (en) 1984-05-15 1984-05-15 PROCESS FOR THE PREPARATION OF PIRIDO-IMIDAZO-RIFAMICINE
IT3463A/84 1984-05-15

Publications (1)

Publication Number Publication Date
US4557866A true US4557866A (en) 1985-12-10

Family

ID=11107845

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/727,521 Expired - Lifetime US4557866A (en) 1984-05-15 1985-04-26 Process for the synthesis of pyrido-imidazo rifamycins

Country Status (18)

Country Link
US (1) US4557866A (en)
EP (1) EP0161534B1 (en)
JP (1) JPS60252483A (en)
AR (1) AR241913A1 (en)
AT (1) ATE46512T1 (en)
AU (1) AU568934B2 (en)
CA (1) CA1215708A (en)
DE (1) DE3573120D1 (en)
DK (1) DK162647C (en)
ES (1) ES543115A0 (en)
FI (1) FI81101C (en)
GR (1) GR851144B (en)
IE (1) IE58392B1 (en)
IT (1) IT1199374B (en)
NO (1) NO164242C (en)
PH (1) PH22007A (en)
PT (1) PT80446B (en)
ZA (1) ZA852971B (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014749A1 (en) * 2001-12-13 2004-01-22 Michaelis Arthur F. Sulfhydryl rifamycins and uses thereof
US20050101598A1 (en) * 2003-11-07 2005-05-12 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210592A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20080014185A1 (en) * 1999-08-11 2008-01-17 Cedars-Sinai Medical Center Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080262220A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Polymorphic forms alpha, beta and gamma of rifaximin
US20080262232A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US20080262012A1 (en) * 2004-11-04 2008-10-23 Giuseppe Claudio Viscomi Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximin
KR100885755B1 (en) 2005-03-03 2009-02-26 알파 와셔만 에스.피.아. New polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
US20090082558A1 (en) * 2007-09-20 2009-03-26 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US20090312357A1 (en) * 2006-09-22 2009-12-17 Cipla Limited Rifaximin
WO2010067072A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
US20100174064A1 (en) * 2008-02-25 2010-07-08 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US20100204173A1 (en) * 2008-10-02 2010-08-12 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100209507A1 (en) * 1999-08-11 2010-08-19 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
US20100239664A1 (en) * 2008-02-25 2010-09-23 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US20100267654A1 (en) * 2009-04-20 2010-10-21 Alfa Wasserman, S.P.A. Rifamycin derivatives
US20110065740A1 (en) * 2008-10-02 2011-03-17 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110071103A1 (en) * 2008-10-02 2011-03-24 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
CN101585843B (en) * 2008-05-21 2011-07-06 重庆赛诺生物药业股份有限公司 Process for preparing rifaximin
US8227482B1 (en) 2011-02-11 2012-07-24 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2014006576A1 (en) 2012-07-06 2014-01-09 Alfa Wassermann S.P.A. Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
US10280177B2 (en) 2006-09-05 2019-05-07 Alfasigma S.P.A. Use of polyols to obtain stable polymorphous forms of rifaximin
CN110770244A (en) * 2017-06-26 2020-02-07 倍尔福股份公司 Antibacterial agent of pyridoimidazole rifamycin derivative
US10556915B2 (en) 2014-03-31 2020-02-11 Euticals Spa Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
US10765667B2 (en) 2008-02-26 2020-09-08 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US11129817B2 (en) 2016-09-30 2021-09-28 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
US11564912B2 (en) 2008-02-26 2023-01-31 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
CA2643364C (en) 2006-03-09 2017-06-06 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
KR20090047490A (en) 2006-08-02 2009-05-12 샐릭스 파마슈티컬스 인코포레이티드 Compositions and methods for the treatment of radiation proctosigmoitis
ITMI20071241A1 (en) * 2007-06-20 2008-12-21 Solmag S P A PROCESS FOR THE PREPARATION OF RIFAXIMINA AMORFA AND RIFAXIMINA AMORPHAS SO OBTAINED
US8309569B2 (en) 2008-02-26 2012-11-13 Salix Pharmaceuticals, Ltd. Methods for treating diarrhea-associated irritable bowel syndrome
DK2294012T3 (en) 2008-05-07 2014-10-06 Salix Pharmaceuticals Ltd Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease
MX2011012829A (en) 2009-06-02 2012-02-28 Salix Pharmaceuticals Ltd Methods of treating hepatic encephalopathy.
AU2010320656B2 (en) 2009-11-23 2015-07-30 Cipla Limited Topical foam composition
WO2011080691A1 (en) 2009-12-28 2011-07-07 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CA2789929C (en) 2010-02-18 2019-11-26 Salix Pharmaceuticals, Ltd. Methods for treating infection
IT1398550B1 (en) 2010-03-05 2013-03-01 Alfa Wassermann Spa RIFAXIMINA COMPREHENSIVE FORMULATIONS USEFUL TO OBTAIN A PROLONGED EFFECT IN TIME
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2012009387A1 (en) 2010-07-12 2012-01-19 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (en) 2011-07-29 2013-01-30 Alfa Wassermann Spa PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS.
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
WO2014140988A1 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
ES2829285T3 (en) 2013-04-12 2021-05-31 Alfasigma Spa Administration of NSAIDs and related compositions, methods and systems
ITMI20131307A1 (en) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A PROCESS FOR THE PREPARATION OF REFAXIMINA K
CN103509038B (en) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 A kind of new crystal rifaximin ζ and preparation method thereof
MX2016014329A (en) 2014-05-04 2017-02-23 Salix Pharmaceuticals Inc Ibs microbiota and uses thereof.
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341785A (en) * 1980-05-22 1982-07-27 Alfa Farmaceutici S.P.A. Imidazo-rifamycin derivatives with antibacterial utility

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341785A (en) * 1980-05-22 1982-07-27 Alfa Farmaceutici S.P.A. Imidazo-rifamycin derivatives with antibacterial utility

Cited By (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110177B2 (en) 1999-08-11 2012-02-07 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20080014185A1 (en) * 1999-08-11 2008-01-17 Cedars-Sinai Medical Center Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth
US7585838B2 (en) 1999-08-11 2009-09-08 Cedars-Sinai Medical Center Methods of treating fibromyalgia caused by small intestinal bacterial overgrowth
US7935799B2 (en) 1999-08-11 2011-05-03 Cedars-Sinai Medical Center Methods of treating diarrhea caused by small intestinal bacterial overgrowth
US8562952B2 (en) 1999-08-11 2013-10-22 Cedars-Sinai Medical Center Methods for manipulating satiety
US20100209507A1 (en) * 1999-08-11 2010-08-19 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
US8388935B2 (en) 1999-08-11 2013-03-05 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20090012113A1 (en) * 1999-08-11 2009-01-08 Cedars-Sinai Medical Center Methods of treating a subject suffering from irritable bowel syndrome
US7718608B2 (en) 1999-08-11 2010-05-18 Cedars-Sinai Medical Center Methods of treating a subject suffering from irritable bowel syndrome
US9358276B2 (en) 1999-08-11 2016-06-07 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7452857B2 (en) 1999-08-11 2008-11-18 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US20090325994A1 (en) * 1999-08-11 2009-12-31 Cedars-Sinai Medical Center Methods of treating diarrhea caused by small intestinal bacterial overgrowth
US7605240B2 (en) 1999-08-11 2009-10-20 Cedara-Sinai Medical Center Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth
US8197805B2 (en) 1999-08-11 2012-06-12 Cedars-Sinai Medical Center Methods of treating autoimmune diseases caused by small intestinal bacterial overgrowth
US7078399B2 (en) 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US20040014749A1 (en) * 2001-12-13 2004-01-22 Michaelis Arthur F. Sulfhydryl rifamycins and uses thereof
US20110086871A1 (en) * 2003-11-07 2011-04-14 Alfa Wassermann, S.P.A. Rifaximin compositions and method of use
US7915275B2 (en) 2003-11-07 2011-03-29 Alfa Wassermann, S.P.A. Use of polymorphic forms of rifaximin for medical preparations
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US20050101598A1 (en) * 2003-11-07 2005-05-12 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
US20080262232A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Processes for the production of polymorphic forms of rifaximin
US20090234114A1 (en) * 2003-11-07 2009-09-17 Alfa Wasserman S.P..A. Polymorphic forms alpha, beta, and gamma of rifaximin
US7612199B2 (en) 2003-11-07 2009-11-03 Alfa Wassermann, S.P.A. Polymorphic forms α, β, and γ of rifaximin
US8158781B2 (en) 2003-11-07 2012-04-17 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262220A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Polymorphic forms alpha, beta and gamma of rifaximin
US8158644B2 (en) 2003-11-07 2012-04-17 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080132530A1 (en) * 2003-11-07 2008-06-05 Alfa Wassermann S.P.A. Use of polymorphic forms of rifaximin for medical preparations
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20110160449A1 (en) * 2003-11-07 2011-06-30 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20110160448A1 (en) * 2003-11-07 2011-06-30 Alfa Wassermann, S.P.A. Polymorphic forms alpha, beta and gamma of rifaximin
US8404704B2 (en) 2003-11-07 2013-03-26 Alfa Wassermann S.P.A. Use of polymorphic forms of rifaximin for medical preparations
US20110152516A1 (en) * 2003-11-07 2011-06-23 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximin
US8173801B2 (en) 2003-11-07 2012-05-08 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7045620B2 (en) 2003-11-07 2006-05-16 Alfa Wassermann, S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262012A1 (en) * 2004-11-04 2008-10-23 Giuseppe Claudio Viscomi Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximin
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210592A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8518949B2 (en) 2005-03-03 2013-08-27 Alfa Wassermann S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US10703763B2 (en) 2005-03-03 2020-07-07 Alfasigma S.P.A. Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
KR100885755B1 (en) 2005-03-03 2009-02-26 알파 와셔만 에스.피.아. New polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
US10280177B2 (en) 2006-09-05 2019-05-07 Alfasigma S.P.A. Use of polyols to obtain stable polymorphous forms of rifaximin
US8633234B2 (en) 2006-09-22 2014-01-21 Cipla Limited Rifaximin
US20090312357A1 (en) * 2006-09-22 2009-12-17 Cipla Limited Rifaximin
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20090082558A1 (en) * 2007-09-20 2009-03-26 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US20100174064A1 (en) * 2008-02-25 2010-07-08 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8754098B2 (en) 2008-02-25 2014-06-17 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US9359357B2 (en) 2008-02-25 2016-06-07 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US9546183B2 (en) 2008-02-25 2017-01-17 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US9034892B2 (en) 2008-02-25 2015-05-19 Salix Pharmaceuticals, Inc. Forms of rifaximin and uses thereof
US9700545B2 (en) 2008-02-25 2017-07-11 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US9181274B2 (en) 2008-02-25 2015-11-10 Karen S. Gushurst Forms of rifaximin and uses thereof
US9273066B2 (en) 2008-02-25 2016-03-01 Salix Pharmaceuticals, Inc. Forms of rifaximin and uses thereof
US20100239664A1 (en) * 2008-02-25 2010-09-23 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8569326B2 (en) 2008-02-25 2013-10-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US10765667B2 (en) 2008-02-26 2020-09-08 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US11564912B2 (en) 2008-02-26 2023-01-31 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
CN101585843B (en) * 2008-05-21 2011-07-06 重庆赛诺生物药业股份有限公司 Process for preparing rifaximin
US9421195B2 (en) 2008-10-02 2016-08-23 Salix Pharmaceuticals, Ltd Methods of treating hepatic encephalopathy
US10709694B2 (en) 2008-10-02 2020-07-14 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US8829017B2 (en) 2008-10-02 2014-09-09 Salix Pharmaceuticals, Ltd. Methods of treating traveler's diarrhea and hepatic encephalopathy
US11633384B2 (en) 2008-10-02 2023-04-25 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US8946252B2 (en) 2008-10-02 2015-02-03 Salix Pharmaceuticals, Ltd Methods of treating traveler's diarrhea and hepatic encephalopathy
US8969398B2 (en) 2008-10-02 2015-03-03 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100204173A1 (en) * 2008-10-02 2010-08-12 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US8642573B2 (en) 2008-10-02 2014-02-04 Salix Pharmaceuticals, Ltd Methods of treating hepatic encephalopathy
US20110065740A1 (en) * 2008-10-02 2011-03-17 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US10335397B2 (en) 2008-10-02 2019-07-02 Salix Pharmaceuticals, Ltd Methods of treating hepatic encephalopathy
US10314828B2 (en) 2008-10-02 2019-06-11 Salix Pharmaceuticals, Ltd Methods of treating hepatic encephalopathy
US20110071103A1 (en) * 2008-10-02 2011-03-24 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US9949958B2 (en) 2008-10-02 2018-04-24 Salix Pharmaceuticals, Ltd Methods of treating hepatic encephalopathy
US9855254B2 (en) 2008-10-02 2018-01-02 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US9629829B2 (en) 2008-10-02 2017-04-25 Salix Pharmaceuticals, Ltd Methods of treating hepatic encephalopathy
US9629828B2 (en) 2008-10-02 2017-04-25 Salix Pharmaceuticals, Ltd. Methods of treating traveler's diarrhea and hepatic encephalopathy
US20110178113A1 (en) * 2008-10-02 2011-07-21 Salix Pharmaceuticals, Ltd Methods of treating traveler's diarrhea and hepatic encephalopathy
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
WO2010067072A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
US20100267654A1 (en) * 2009-04-20 2010-10-21 Alfa Wasserman, S.P.A. Rifamycin derivatives
US8318763B2 (en) 2009-04-20 2012-11-27 Alfa Wassermann S.P.A. Rifamycin derivatives
CN105254647A (en) * 2010-02-19 2016-01-20 萨利克斯药品有限公司 Forms of rifaximin and uses thereof
US8227482B1 (en) 2011-02-11 2012-07-24 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8735419B2 (en) 2011-02-11 2014-05-27 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US9133217B2 (en) 2011-02-11 2015-09-15 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US8507517B2 (en) 2011-02-11 2013-08-13 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2014006576A1 (en) 2012-07-06 2014-01-09 Alfa Wassermann S.P.A. Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
US9452157B2 (en) 2012-07-06 2016-09-27 Alfa Wassermann S.P.A Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof
EP3127909A1 (en) 2012-07-06 2017-02-08 ALFA WASSERMANN S.p.A. Crystalline forms of rifaximin and their preparation in the presence of amino acids
US9186355B2 (en) 2013-07-26 2015-11-17 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US11739099B2 (en) 2014-03-31 2023-08-29 Curia Ip Holdings, Llc Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
US10556915B2 (en) 2014-03-31 2020-02-11 Euticals Spa Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
US10745415B2 (en) 2014-03-31 2020-08-18 Amri Italy S.R.L. Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
US10961257B2 (en) 2014-03-31 2021-03-30 Amri Italy S.R.L. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
US10428086B2 (en) 2014-05-12 2019-10-01 Alfasigma S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
US11311521B2 (en) 2016-09-30 2022-04-26 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
US11129817B2 (en) 2016-09-30 2021-09-28 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
US11660292B2 (en) 2016-09-30 2023-05-30 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN110770244A (en) * 2017-06-26 2020-02-07 倍尔福股份公司 Antibacterial agent of pyridoimidazole rifamycin derivative

Also Published As

Publication number Publication date
IE58392B1 (en) 1993-09-08
AU4251585A (en) 1985-11-21
IT8403463A0 (en) 1984-05-15
DE3573120D1 (en) 1989-10-26
DK162647C (en) 1992-04-13
AR241913A1 (en) 1993-01-29
PT80446A (en) 1985-06-01
DK214685A (en) 1985-11-16
ES8603489A1 (en) 1986-01-01
ATE46512T1 (en) 1989-10-15
IT1199374B (en) 1988-12-30
AU568934B2 (en) 1988-01-14
EP0161534A2 (en) 1985-11-21
FI81101B (en) 1990-05-31
CA1215708A (en) 1986-12-23
FI851907A0 (en) 1985-05-14
IE851191L (en) 1985-11-15
PT80446B (en) 1987-11-11
EP0161534A3 (en) 1987-03-04
JPS60252483A (en) 1985-12-13
NO164242C (en) 1990-09-12
NO164242B (en) 1990-06-05
DK162647B (en) 1991-11-25
JPH0469634B2 (en) 1992-11-06
FI81101C (en) 1990-09-10
FI851907L (en) 1985-11-16
ES543115A0 (en) 1986-01-01
PH22007A (en) 1988-05-02
DK214685D0 (en) 1985-05-14
EP0161534B1 (en) 1989-09-20
ZA852971B (en) 1985-12-24
GR851144B (en) 1985-11-25
NO851921L (en) 1985-11-18

Similar Documents

Publication Publication Date Title
US4557866A (en) Process for the synthesis of pyrido-imidazo rifamycins
SE453089B (en) IMIDAZO RIFAMYCINE DERIVATIVES, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITION
US4007169A (en) Method of preparing derivatives of rifamycin S
CA1215976A (en) New process for the synthesis of imidazo rifamycins
CA1218650A (en) Process for the synthesis of pyrido-imidazo- rifamycins
HU194272B (en) Process for producing 7,16-dioxa-2-aza-10-0-kladinosyl-12-0-dezozaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl-bicyclo-square bracket opened-11,2,1-square bracket closed-hexadeca-1/2/-en-8-one
US4880825A (en) Mitomycin derivatives
US4374774A (en) Mitomycins
EP0131232B1 (en) Stereoselective process for the preparation of anthracycline derivatives
US4959495A (en) Process for the preparation of intermediates used to produce aminothiazoloximino cephalosporins
US4316842A (en) Penicillin intermediates
US4659812A (en) Cephalosporin intermediates
CA2101789A1 (en) Process for the preparation of imidazopyridines
US4603212A (en) Analogs of the antibiotic spectinomycin
EP0228546B1 (en) Method for the preparation of 4'-0-tetrahydropyranyladriamycin b
KR100390548B1 (en) Method for manufacturing cephalosporin intermediate
EP0717045B1 (en) Process for producing indolocarbazole derivative
WO1991017997A1 (en) PROCESS FOR THE PREPARATION OF 7α-ALKOXYCEPHEM DERIVATIVES
US6162910A (en) Process for preparing lipophilic oligosaccharide antibiotics
US4603196A (en) Process for the preparation of β-methyldigoxin
KR100202279B1 (en) Process for preparing cefuroxime ester derivatives
KR850001960B1 (en) Process for preparing cephalosporin derivatives
KR860001087B1 (en) Process for preparing cephalosporanic acid derivatives
US4225717A (en) 2-Hydrazino-3-pyridinol-1-oxide hydrobromide
US4393205A (en) Cephapirine esters and salts thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALFA FARMACEUTICI S.P.A., VIA RAGAZZI DEL 99 N 5,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:PIANI SILVANO;MARCHI, EGIDIO;CANNATA, VINCENZO;AND OTHERS;REEL/FRAME:004427/0766

Effective date: 19850614

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment